2022 Fiscal Year Final Research Report
Challenge to paradigm shift in head and neck cancer treatment
| Project/Area Number |
19K22699
|
|---|
| Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Medium-sized Section 57:Oral science and related fields
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-06-28 – 2023-03-31
|
| Keywords | がん |
|---|
| Outline of Final Research Achievements |
In immunotherapy, immune checkpoint inhibitors have been effective to tumor, but the response rate is about 20%. Therefore, more effective treatment has been desired. This requires a tumor-specific immune response. Using the third-generation T cell receptor repertoire analysis technology developed by the applicants, I aimed to establish a foundation for a new tumor immunotherapy using tumor-specific T cell receptors. Using a soluble form of tumor-specific T cell receptor, binding to target cells was investigated. Tumor-specific T cell receptors could bind to target cell specifically. This method may lead to the development of new therapy using tumor-specific T cell receptor.
|
| Free Research Field |
免疫学
|
| Academic Significance and Societal Importance of the Research Achievements |
免疫チェックポイント阻害薬の登場で、がんの免疫療法が注目されているが、奏効率が20％程度であり、より効果的な治療法が望まれていた。本研究は、応募者らが開発した第3世代T細胞受容体レパートリー解析技術を用いた、がん特異的T細胞受容体の特定について、遺伝子配列情報の提供だけでなく、実際に、がん特異的T細胞受容体が、がん細胞に結合することを示した点、T細胞受容体のヘテロダイマーを構築する技術を開発した点、可溶型T細胞受容体を作製した点に学術的意義がある。また、可溶型T細胞受容体は、新たながん治療法の開発に道筋をつけるものであり、社会的意義も大きい。
|
